NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO

Press Release
EXERCISE OF GREENSHOE OPTION
FINAL ANNOUNCEMENT ON STABILISATION MEASURES

Rome, December 6, 2018 - Garofalo Health Care S.p.A. (the “Company” or “GHC”) announces that on December 5, 2018, Equita SIM S.p.A., as agent for the stabilisation of ordinary GHC shares, fully exercised, on behalf of Credit Suisse and Equita SIM S.p.A. – as Joint Global Coordinators - the greenshoe option for n. 2,000,000 ordinary company shares. With the exercise of the greenshoe option, the stabilisation period ends with immediate effect.

The acquisition price of the shares from the greenshoe option is Euro 3.34 per share – corresponding to the offer price established for the institutional placement – for a total amount of Euro 6,680,000.00, gross of the commissions for the institutional placement.

The settlement and value date of the greenshoe option shall be December 7, 2018 and, on the same date the shares from the exercise of the greenshoe option shall be assigned to the shareholder Maria Laura Garofalo in completion of the over-allotment option granted by the former to the Joint Global Coordinators.

Including the shares from the greenshoe option, the institutional placement consists therefore of n. 22,000,000 ordinary GHC shares, equal to approx. 26.8% of the share capital.

In addition, also according to that announced by Equita SIM S.p.A., as agent for the stabilisation of the ordinary GHC shares and also its behalf, GHC announces that during the stabilisation period, from the initial date of trading of ordinary GHC shares on the Mercato Telematico Azionario (Main Stock Exchange) organised and managed by Borsa Italiana S.p.A. (November 9, 2018) until today, no stabilization transaction was undertaken.

This press release is issued also on behalf of Equita SIM S.p.A. as per article 8, letter f) and article 6, paragraph 3 of Delegated Regulation (EU) 2016/1052.

***

Credit Suisse and Equita SIM S.p.A. acted as Joint Global Coordinators and Joint Bookrunners. Equita SIM S.p.A. in addition acts as sponsor. Lazard acts as the company’s financial advisor.

Gianni, Origoni, Grippo, Cappelli & Partners and Shearman & Sterling provide legal support to the company, respectively, regarding Italian law and US and English law, while Linklaters provide legal assistance to the Joint Global Coordinators and to the sponsor. Studio Associato Tributario Bagnera & Associati provides tax assistance to the company. EY is the Independent Audit Firm.
FOR FURTHER DETAILS:
Garofalo Health Care S.p.A.
Mimmo Nesi - Investor Relator
Tel. +39 06 68489231 - ir@garofalohealthcare.com
Website: www.garofalohealthcare.com

Press Office
Community – Communication Advisers
Auro Palomba – Marco Rubino – Giuliana Pampani – Ph.+390289404231 - marco@communitygroup.it

* * *

The GHC Group
The GHC Group, listed on the Milan Stock Exchange, is an Italian accredited private healthcare leader operating through eighteen healthcare facilities demonstrating excellence, located in Italy's strongest regions and offering a comprehensive range of services covering all areas of healthcare thanks to diversified specialties, the use of cutting-edge technologies and highly-qualified personnel. The Group in fact operates across six regions in Northern and Central Italy (Piedmont, Veneto, Emilia Romagna, Liguria, Tuscany and Lazio), covering in the hospital sector acute admissions, long hospitalization, post-acute rehabilitations and outpatient services (the “Hospital Sector”), and in the regional and social-care sector covering residential admissions and district outpatient services (the “Dependency Care Sector”).

As of 31 December 2017, the GHC Group reported total revenue and other income of Euro 136.7 million and an operating EBITDA of Euro 24.9 million (total revenue and other income Pro-forma of Euro 152.2 million, Pro-forma Operating EBITDA of Euro 27.4 million). For the nine months period ending on 30 September 2018, the GHC Group reported total revenue and other income of Euro 115.3 million (up +17.2% on the results as of 9M 2017) and an Operating EBITDA of Euro 22.2 million (up +25.4% on the same period of the previous year).

* * *
These materials are not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Canada, Australia and Japan (or in any other jurisdiction where it is unlawful to do so). This communication does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended (the “Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States, Canada, Australia and Japan or in any other jurisdiction where it is unlawful to do so. This document is being distributed only by or with the approval of an authorised person or to (i) persons who are outside the United Kingdom (ii) persons in the United Kingdom who have professional experience in matters related to investments and who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) of the United Kingdom (the “Order”) (iii) persons who fall within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc.”) of the Order, and (iv) any other persons to whom this document may otherwise lawfully be directed (all such persons together being referred to as “relevant persons”). The investments to which this document relates are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such investments will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This document is an advertisement and is not a prospectus for the purposes of the Directive 2003/71/EC of the European Parliament at the Council of November 4th, 2003, as amended, in particular by Directive 2010/73/UE (together, the “Prospectus Directive”). A prospectus prepared pursuant to the Prospectus Directive will be published exclusively for the purposes of the listing of the Company’s shares on the MTA. An international offering circular will be made available in connection with the Offering described below. Investors should not subscribe for any securities referred to in this document except on the basis of information contained or the international offering circular which include detailed information regarding the Company and the risks involved in investing in the securities. In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/UE, to the extent implemented by the relevant Member State) and includes any relevant implementing measure in the relevant Member State. In the United Kingdom, the Shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the Shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

This announcement contains inside information within the meaning of Article 7(1) of Regulation (EU) no. 596/2014. Upon publication of this announcement, this inside information is now considered to be in the public domain, and any persons previously in possession of such inside information will no longer be considered to be in possession of inside information following publication of this announcement.

The distribution of this press release is not made, and has not been approved, by an “authorized person” within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. As a consequence, this press release is directed only at persons who (i) are located outside the United Kingdom, (ii) have professional experience in matters relating to investments and fall within Article 19(5) (“investment professionals”) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended), (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (iv) are persons to whom this press release may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). This press release is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000.

Garofalo Health Care s.p.a. - Share Capital: Euro 21,000,000 fully paid-in
Economic & Administrative Register Rome No. 947074 - VAT and Tax No. 06103021009
Registered office: Piazzale delle Belle Arti, 6 – 00196 Main Rome No. 06 684891 – Fax 06 68489201
The distribution of this document in certain countries may constitute a breach of applicable law. The information contained in this document does not constitute an offer of securities for sale in Canada, Australia or Japan. This press release may not be published, forwarded or distributed, directly or indirectly, in Canada, Australia or Japan.

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares of the Company (the “Shares”) have been subject to a product approval process, which has determined that such Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II to such target market (the “Target Market Assessment”). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Shares may decline and investors could lose all or part of their investment; the Shares offer no guaranteed income and no capital protection; and an investment in the Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offering. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Global Coordinators and Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Shares and determining appropriate distribution channels.

No representation or warranty, express or implied, is made by Credit Suisse and Equita SIM S.p.A. (the “Managers”), or any of their respective affiliates, directors, officers, employees, advisers or agents as to the accuracy or completeness or verification of the information contained in this announcement, and nothing contained herein is, or shall be relied upon as, a promise or representation by the Managers in this respect, whether as to the past or future.

None of the Managers assumes any responsibility for its accuracy, completeness or verification and accordingly the Managers disclaim, to the fullest extent permitted by applicable law, any and all liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or any such statement.

The Managers are each acting exclusively for the Company in the transaction referred to in this announcement and for no-one else in connection with any transaction mentioned in this announcement and will not regard any other person (whether or not a recipient of this announcement) as a client in relation to any such transaction and will not be responsible to any other person for providing the protections afforded to their respective clients, or for advising any such person on the contents of this announcement or in connection with any transaction referred to in this announcement. The contents of this announcement have not been verified by the Managers.